Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346258 | 0.86 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPTLMNACA1 | |
| SCHEMBL6344219 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HPGDMAPTLMNACA1 | |
| SCHEMBL2039734 | 0.75 | ALDH1A1 (0.63) | ALDH1A1HPGDMAPTLMNACA1 | |
| SCHEMBL29788029 | 0.75 | ALDH1A1 (0.63) | ALDH1A1HPGDMAPTLMNACA1 | |
| SCHEMBL2803303 | 0.71 | LMNA (0.58) | ALDH1A1HPGDMAPTLMNACA1 | |
| SCHEMBL15869819 | 0.71 | ALDH1A1 (0.49) | ALDH1A1HPGDMAPTLMNAKDM4E | |
| SCHEMBL5150983 | 0.70 | SMN1; SMN2 (0.66) | ALDH1A1HPGDMAPTLMNAKDM4E | |
| SCHEMBL6248458 | 0.69 | LMNA (0.68) | ALDH1A1LMNACA1CA2CA12 | |
| SCHEMBL196223 | 0.69 | CA12 (0.68) | ALDH1A1HPGDMAPTCA1CA2 | |
| SCHEMBL25254029 | 0.69 | LMNA (0.45) | ALDH1A1HPGDMAPTLMNACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101651-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | JOHNSON THEODORE O JR (US) | 2005-05-12 | — | — | US | disclosed |
| US-6872745-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20030225042-A1 | Antipicornaviral compounds and compositions, their uses, and materials for their synthesis | JOHNSON THEODORE O (US) | 2003-12-04 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1274682-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| US-20020006943-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001079167-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101651-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | ALDH1A1 4161/4885HPGD 2825/4885MAPT 1852/4885 |
| US-20030225042-A1 | Antipicornaviral compounds and compositions, their uses, and materials for their synthesis | RNASEL, SARNP, RNASEH1 | ALDH1A1 3835/4885HPGD 3379/4885MAPT 2045/4885 |
| US-20020006943-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SERPINB1 | ALDH1A1 3708/4885HPGD 2900/4885MAPT 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.